NCT07532876

Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain

Comparison of Efficacy and Safety of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain

• Status: Enrolling By Invitation
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Pak Emirates Military Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to provide direct evidence on the relative effectiveness and safety of Elagolix versus OCPs, helping physicians make more tailored treatment decisions.

Detailed description

Eligible patients will be assigned to one of two groups: Elagolix 150 mg once daily or OCPs daily, based on physician recommendation and patient preference. Baseline demographic and clinical information will be recorded. Pain outcomes (dysmenorrhea, dyspareunia, non menstrual pain) will be assessed on the NRS at baseline, 12 weeks, and 24 weeks. Adverse events will be documented throughout.

Conditions

• Endometriosis (Diagnosis)

Interventions

Type	Name	Description
DRUG	Elagolix	Elagolix will be administered at 150 mg once daily in this study.
DRUG	Oral Contraceptive (OC)	In this study, administered once daily in a continuous 28-day cycles for 3 months

Timeline

• Start date: 2026-05-01
• Primary completion: 2026-10-01
• Completion: 2026-11-01
• First posted: 2026-04-16
• Last updated: 2026-04-16

Locations

1 site across 1 country: Pakistan

Regulatory

• FDA-regulated drug study